Investment Rating - The report maintains a "Buy" rating for Antu Biology (603658) [1][7] Core Views - The company reported better-than-expected profits in Q1 2024, with new products anticipated to drive future growth [1] - In 2023, the company achieved a revenue of 4.444 billion yuan, a slight increase of 0.05% year-on-year, and a net profit of 1.217 billion yuan, up 4.28% year-on-year [4][5] - The first quarter of 2024 saw a revenue of 1.089 billion yuan, representing a growth of 5.09%, and a net profit of 324 million yuan, which is a significant increase of 33.93% year-on-year [4][5] Summary by Sections Financial Performance - In 2023, the company's total revenue was 44.44 billion yuan, with a 16.64% growth when excluding COVID-19 testing revenue [5] - The revenue from immunology products grew by 23.77% to 2.483 billion yuan, while microbiological and biochemical products also showed strong growth [5] - The overall gross margin improved by 5.23 percentage points to 65.07% in 2023, driven by an increase in the proportion of high-margin reagent products [7] Product Development - The company successfully registered 60 new product certificates in 2023, expanding its product range [5] - New instruments, including the AutoChem B801 series and the Autof ms series, received medical device registration, enhancing the company's technological capabilities [5] Regional Performance - Domestic revenue decreased by 1.82% to 41.59 billion yuan, while overseas revenue surged by 60.53% to 2.09 billion yuan [5] Future Projections - Revenue forecasts for 2024-2026 are 51.31 billion yuan, 60.48 billion yuan, and 71.07 billion yuan, with expected growth rates of 15%, 18%, and 18% respectively [7] - Projected net profits for the same period are 1.515 billion yuan, 1.891 billion yuan, and 2.347 billion yuan, with growth rates of 24% for each year [7]

Investment Rating - The report assigns a "Buy" rating for the company, indicating a strong performance relative to the benchmark [7]. Core Views - The company's immune business shows robust growth, with significant improvement in profitability in Q1 2024. In 2023, the company achieved revenue of 4.444 billion yuan, a slight increase of 0.05% year-on-year, and a net profit of 1.217 billion yuan, up 4.28% year-on-year [1][2]. - The company has established a comprehensive marketing network covering approximately 62% of tertiary hospitals in China and has made significant strides in international expansion, with overseas revenue reaching 209 million yuan in 2023, a 61% increase year-on-year [1][2]. - The company has increased its R&D investment, leading to improved product structure and profitability. The gross profit margin in 2023 was 65%, an increase of about 5.2 percentage points from 2022 [1][2]. Financial Performance Summary - In 2023, the company's immune diagnostic business generated revenue of 2.483 billion yuan, a 24% increase year-on-year. The microbiological testing segment achieved 323 million yuan, up 19% year-on-year, while biochemical testing revenue was 250 million yuan, up 21% year-on-year [1][2]. - The company forecasts revenues of 5.116 billion yuan, 6.018 billion yuan, and 7.160 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 15.1%, 17.6%, and 19.0% [1][2]. - The projected net profits for the same years are 1.543 billion yuan, 1.904 billion yuan, and 2.340 billion yuan, with growth rates of 26.7%, 23.4%, and 22.9% respectively [1][2]. Key Financial Metrics - The gross profit margin is expected to remain stable, with slight improvements projected over the next few years, reaching 66.0% by 2026 [2][3]. - The company's earnings per share (EPS) is projected to increase from 2.08 yuan in 2023 to 3.99 yuan by 2026 [2][3]. - The price-to-earnings (P/E) ratio is expected to decrease from 26.14 in 2023 to 13.60 by 2026, indicating a potentially more attractive valuation over time [2][3].

证券研究报告 公 2024年04月21日 司 报 告 安图生物(603658) │ 行 业： 医药生物/医疗器械 公 投资评级： 买入（维持） 司 当前价格： 54.28元 年 多产线稳步增长，盈利能力持续改善 目标价格： 71.62元 报 点 事件： 评 基本数据 公司发布2023年年报，全年实现营收44.44亿元（yoy+0.05%），归母净 总股本/流通股本(百万股) 586.27/586.27 利润12.17亿元（yoy+4.28%），扣非归母净利润11.85亿元（yoy+5.86%）。 流通A股市值(百万元) 31,822.86 2024年Q1公司实现营收10.89亿元（yoy+5.09%），归母净利润3.24亿 每股净资产(元) 14.98 元（yoy+33.93%），扣非归母净利润3.14亿元（yoy+33.15%）。 资产负债率(%) 23.71 一年内最高/最低(元) 66.36/41.01 ➢ 多产线稳步增长 2023 年公司实现试剂类营收 38.15 亿元（yoy+8.06%），其中免疫诊断、 股价相对走势 微生物检测、生化检测营收分别为24.83亿元、3.23亿元、2.50亿元，同 安 ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 65.48 CNY for 2024 [1][3]. Core Views - The company's Q1 profit exceeded expectations, with a notable growth in revenue and net profit [1]. - The internal business growth remains stable, and the improvement in business structure has enhanced profit levels [1]. - The company is positioned as a pioneer in the IVD platform in China, with strong potential for future acceleration [1]. Financial Performance Summary - For the year 2023, the company reported a total revenue of 4.44 billion CNY, a slight increase of 0.05%, with a 16.6% growth when excluding COVID-19 testing revenue. The net profit attributable to the parent company was 1.22 billion CNY, up 4.3% [1][6]. - In Q1 2024, revenue reached 1.09 billion CNY, reflecting a year-on-year increase of 5.1%, while the net profit attributable to the parent company surged by 33.9% to 324 million CNY [1][6]. - The reagent business generated 3.81 billion CNY in revenue for 2023, with a gross margin of 70.94%, while instrument revenue fell to 480 million CNY, with a gross margin of 33.54% [1][6]. Business Segment Analysis - The immunodiagnostics segment saw revenue of 2.48 billion CNY, growing by 23.8%, with a gross margin increase to 80.1% [1]. - The microbiological testing segment reported revenue of 320 million CNY, up 18.7%, maintaining a gross margin of 45.08% [1]. - The biochemical testing segment achieved revenue of 250 million CNY, with a growth of 20.54% and a slight gross margin increase to 63.4% [1]. Geographic Revenue Breakdown - Domestic revenue was 4.16 billion CNY, down 1.82%, but with a gross margin improvement to 67.39% [1]. - International revenue reached 210 million CNY, marking a significant increase of 60.5%, with a gross margin rise to 37.8% [1]. Future Earnings Forecast - The company is projected to have EPS of 2.6 CNY, 3.2 CNY, and 4.0 CNY for the years 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 21, 17, and 14 [1][6].

医药 公 2024年04月19日 司 报 安图生物(603658.SH) 告 2023年剔新冠双位数营收增长，24Q1反腐影响仍在持续 推荐 ( 维持 ) 事项： 公司发布2023年报和2024年第一季度财报： 股价:54.28元 2023年实现营业收入44.44亿元（YoY +0.0%）；归母净利润为12.17亿元 公 主要数据 （YoY +4.3%）；归母扣非净利润为11.85亿元（YoY +5.9%）。基本符合市 行业 安图生物 司 场预期。 公司网址 www.autobio.com.cn ...

Investment Rating - The report maintains a "Recommended" rating for the company [1][2]. Core Insights - The company reported a revenue of 44.44 billion yuan in 2023, a slight increase of 0.05% year-on-year, with a net profit of 1.22 billion yuan, up 4.28% [1]. - The first quarter of 2024 showed significant performance exceeding expectations, with a revenue of 10.89 billion yuan, representing a 5.09% increase, and a net profit of 3.24 billion yuan, up 33.93% [1]. - The company’s core business, particularly in chemiluminescence and molecular diagnostics, is experiencing rapid growth, contributing to an improved revenue structure [1][2]. Financial Performance Summary - In 2023, the company achieved a total revenue of 44.44 billion yuan, with a net profit of 1.22 billion yuan and an operating cash flow of 1.47 billion yuan [1]. - The projected revenues for 2024 to 2026 are 50.49 billion yuan, 60.70 billion yuan, and 72.85 billion yuan respectively, with expected net profits of 1.55 billion yuan, 1.94 billion yuan, and 2.39 billion yuan [3][4]. - The gross margin is expected to remain stable, with slight fluctuations projected over the next few years [3]. Business Growth Drivers - The company has entered over 6,700 secondary hospitals, including more than 2,200 tertiary hospitals, capturing 61.90% of the total tertiary hospital market in China [1]. - The overseas business has shown robust growth, with a revenue increase of 60.53% in 2023, reaching 2.09 billion yuan [1]. - The company’s R&D investment was 6.56 billion yuan in 2023, accounting for 14.77% of revenue, indicating a strong commitment to innovation and product development [1][4]. Future Outlook - The company is expected to continue its strong growth trajectory, with projected net profit growth rates of 27.56%, 24.85%, and 23.21% for 2024, 2025, and 2026 respectively [2][3]. - The report highlights the potential for further market penetration and revenue growth driven by the expansion of its product offerings and the increasing demand for domestic alternatives in the healthcare sector [1][2].

安图生物23年报及24一季报交流240419原文 2024年04月19日11:36 发言人100:00 防二道贩子搬运转卖 发言人200:24 设运转卖， 昨天晚上公司的这个财报发布出来之后，相信大家的关注度非常高。我们可以看到2023年，公司的业绩 非常平稳。2024年的一季度的业绩，应该是比大家想象的要更好一些。所以今天我们也请公司两位领导 来跟各位交流一下公司的这个经营状态，以及对2024年全年的一个展望。今天的交流，首先请黄总跟各 位介绍一下年报以及一报的一个业绩经营情况。后面接下来请与会的各家券商分析师老师先跟向公司管 理层提问。最后再如果有没有时间的话，请线上投资者提问。好的，方总，首先请您大概介绍一下业绩 情况。 发言人301:42 好的，各位投资者，各位家长朋友，大家早早上好。业绩的一年报和一季报的经营情况，我估计大家都 看到了。去年的收入去年那个收入和利润，今年的收入，一季报的利润和收入都大家都知道了，我就不 再耽误大家时间，我把可能个别代理，个别很个别投资者没有看到我们的今天那个就是几个拆分情况。 发言人302:06 更多内容关注” 搬运转卖， 发言人302:23 核酸点的实际是1740万 ...

关于郑州安图生物工程股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表的专项审计报告 目 录 1、 专项审计报告 2、 附表 委托单位：郑州安图生物工程股份有限公司 审计单位：中勤万信会计师事务所(特殊普通合伙) 联系电话：0371-86506868 关于对郑州安图生物工程股份有限公司 控股股东及其他关联方占用资金情况 的专项说明 勤信专字【2024】第 0597 号 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）"进行查导 报告编码:京247PJ | 容 内 | 页 次 | | --- | --- | | 控股股东及其他关联方占用 | 1-2 | | 资金情况的专项说明 | | | 附表 | | | | 3 | 目 录 中勤万信会计师事务所 地址:北京西直门外大街 112 号阳光大厦 10 层 电话:(86-10) 68360123 传真:(86-10)68360123-3000 邮编:100044 关于郑州安图生物工程股份有限公司 控股股东及其他关联方占用资金情况 的专项说明 根据中国证券监督管理委员会发布的《上市公司监管指引第 8 号 - ...

www.autobio.com.cn 郑州安图生物工程股份有限公司 安图生物社会责任报告 2023 致力于医学实验室技术的普及和提高，为人类健康服务。 报告编制说明 郑州安图生物工程股份有限公司（简称"安图生物""公司"）社会责任报告，以客观、规范为原则， 全面披露公司在企业治理、企业高质量和可持续发展、股东及员工权益保障以及承担社会责任等方面所 做的工作和成效。 报告范围 本报告为2023年度报告，涵盖2023年1月1日至2023年12月31日相关数据，同时涉及公司成立以来的相关情况。 本报告覆盖的范围包括安图生物及所属子公司。 编制依据 上海证券交易所《上海证券交易所上市公司自律监管指引第1号⸺规范运作》。 报告说明 安图生物保证本报告不存在任何虚假记载和误导性陈述，数据与《郑州安图生物工程股份有限公司2023年年度报 告》披露的相同指标一致。 获取方式 本报告以纸质版和电子版两种形式发布，您可在上海证券交易所指定信息披露网站或登录公司网站阅读。 目 录 CONTENTS | 综述 | | | --- | --- | | 接续奋斗 砥砺前行 再谱新篇 | 01 | | 关键绩效 | | | | 03 | ...

证券代码：603658 证券简称：安图生物 公告编号：2024-029 郑州安图生物工程股份有限公司 关于开展外汇套期保值业务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、交易情况概述 （一）交易目的 交易目的：为有效规避外汇市场的风险，防范汇率大幅波动对公司经营 业绩造成不利影响，提高外汇资金使用效率，郑州安图生物工程股份有 限公司（以下简称"公司"）及控股子公司拟开展外汇套期保值业务，旨 在平抑外汇敞口风险、合理降低财务费用、增强财务稳健性。 交易品种和交易金额：最高额（任一时点合计，含收益进行再交易的相 关金额）不超过 3,000 万美元（或等值货币，含本数）开展外汇套期保 值，交易币种包括但不限于美元、欧元、日元等与实际业务相关的币种。 交易工具和交易场所：包括远期结售汇、外汇掉期、外汇期权、利率互 换、利率掉期、利率期权等相关衍生品的单一产品或产品组合，对应基 础资产包括利率、汇率、货币等。交易场所包括场内和场外。 已履行的审议程序：已经公司第四届董事会第十五次会议、第四届监事 会第 ...